ANI PHARMACEUTICALS, INC Increase (Decrease) in Royalties Payable
ANI PHARMACEUTICALS, INC (ANIP) reported Increase (Decrease) in Royalties Payable of -$2.93 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRoyaltiesPayable · last filed 2019-11-06
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for the quarter ending 2019-09-30 was -$738.00K.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for the quarter ending 2019-06-30 was $825.00K.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for the quarter ending 2019-03-31 was -$3.02M.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for the quarter ending 2018-12-31 was $1.00M, a 136.64% increase year-over-year.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for fiscal 2018 was -$3.71M.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for fiscal 2017 was -$417.00K, a 106.65% decline from fiscal 2016.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for fiscal 2016 was $6.27M.
- ANI PHARMACEUTICALS, INC increase (decrease) in royalties payable for fiscal 2015 was -$96.00K, a 113.68% decline from fiscal 2014.
| Period end | Increase (Decrease) in Royalties Payable 3 month | Increase (Decrease) in Royalties Payable 6 month | Increase (Decrease) in Royalties Payable 9 month | Increase (Decrease) in Royalties Payable 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$738.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $87.00K derived: sum of 2 quarters · filed 2019-11-06 | -$2.93M 10-Q · filed 2019-11-06 | -$1.93M derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | $825.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$2.19M 10-Q · filed 2019-08-07 | -$1.19M derived: sum of 3 quarters · filed 2019-08-07 | -$1.95M derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-03-31 | -$3.02M 10-Q · filed 2019-05-09 | -$2.02M derived: sum of 2 quarters · filed 2019-05-09 | -$2.78M derived: sum of 3 quarters · filed 2019-11-06 | -$5.92M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $237.00K derived: sum of 2 quarters · filed 2019-11-06 | -$2.90M derived: sum of 3 quarters · filed 2019-11-06 | -$3.71M 10-K · filed 2019-02-27 |
| 2018-09-30 | -$764.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$3.91M derived: sum of 2 quarters · filed 2019-11-06 | -$4.71M 10-Q · filed 2019-11-06 | -$4.29M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$3.94M 10-Q · filed 2019-08-07 | -$3.52M derived: sum of 3 quarters · filed 2019-08-07 | -$3.66M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | -$803.00K 10-Q · filed 2019-05-09 | -$380.00K derived: sum of 2 quarters · filed 2019-05-09 | -$519.00K derived: sum of 3 quarters · filed 2019-05-09 | $1.03M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $284.00K derived: sum of 2 quarters · filed 2019-02-27 | $1.83M derived: sum of 3 quarters · filed 2019-02-27 | -$417.00K 10-K · filed 2019-02-27 |
| 2017-09-30 | -$139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.41M derived: sum of 2 quarters · filed 2018-11-06 | -$840.00K 10-Q · filed 2018-11-06 | -$653.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$701.00K 10-Q · filed 2018-08-07 | -$514.00K derived: sum of 3 quarters · filed 2019-02-27 | $3.15M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$2.25M 10-Q · filed 2018-05-08 | -$2.06M derived: sum of 2 quarters · filed 2019-02-27 | $1.60M derived: sum of 3 quarters · filed 2019-02-27 | $1.19M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.85M derived: sum of 2 quarters · filed 2019-02-27 | $3.44M derived: sum of 3 quarters · filed 2019-02-27 | $6.27M 10-K · filed 2019-02-27 |
| 2016-09-30 | $3.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $3.25M derived: sum of 2 quarters · filed 2017-11-02 | $6.08M 10-Q · filed 2017-11-02 | $6.50M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$404.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $2.42M 10-Q · filed 2017-08-03 | $2.84M derived: sum of 3 quarters · filed 2018-02-27 | $2.55M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $2.83M 10-Q · filed 2017-05-04 | $3.24M derived: sum of 2 quarters · filed 2018-02-27 | $2.95M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2015-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $124.00K derived: sum of 2 quarters · filed 2018-02-27 | -$96.00K 10-K · filed 2018-02-27 | |
| 2015-09-30 | -$291.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$511.00K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | -$220.00K 10-Q · filed 2016-08-04 | |||
| 2014-12-31 | $702.00K 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |